Contribution of MLKL to the development of doxorubicin-induced cardiomyopathy and its amelioration by rapamycin.
Shimizu M, Ohwada W, Yano T, Kouzu H, Sato T, Ogawa T, Osanami A, Toda Y, Nagahama H, Tanno M, Miura T, Kuno A, Furuhashi M.
Shimizu M, et al. Among authors: nagahama h.
J Pharmacol Sci. 2024 Sep;156(1):9-18. doi: 10.1016/j.jphs.2024.06.005. Epub 2024 Jun 27.
J Pharmacol Sci. 2024.
PMID: 39068035
Free article.